pharmaceutical

May 062013
 
South Africa - Life-saving HIV drugs fuel crime and addiction (Amar Toor)

Three years ago, Sipho Molefe (not his real name) was a normal 16-year-old boy — an athletic, easygoing high schooler who was well liked among his peers in rural South Africa. Today, Sipho is unemployed, gaunt, and mired in a life of crime outside Durban, where he and untold others have been gripped by a [...]

Apr 092013
 
South Africa - New one-pill, $10-per-month anti-retroviral AIDS treatment debuts

South Africa’s health minister on Monday launched a new single dose anti-AIDs drug which will simplify the world’s biggest HIV treatment regime to just one life-saving pill a day. The three-in-one combination anti-retroviral (ARV) was secured at a record-low price and will cost the state 89 rand a month ($10, eight euros) per patient. “Before [...]

Apr 022013
 
ACT UP/Paris - Le laboratoire Novartis débouté par la Cour suprême indienne : soulagement des malades et des activistes du monde entier

The supreme Court of New Delhi today dismissed the Swiss laboratory Novartis with its complaint against the Indian State, after seven years of procedure. Since 2006, the pharmaceutical group was trying to get a patent on the reformulation of an existing anti-cancer molecule, Gleevec. Pursuant to the Indian Act on patents [1], the India had [...]

Mar 122013
 
USA - Unreported side effects of drugs are found using internet search data, study finds

Using data drawn from queries entered into Google, Microsoft and Yahoo search engines, scientists at Microsoft, Stanford and Columbia University have for the first time been able to detect evidence of unreported prescription drug side effects before they were found by the Food and Drug Administration’s warning system. Using automated software tools to examine queries by [...]

Mar 122013
 
USA - How much money has your doctor been paid by pharmaceutical companies?

Dr. Jon W. Draud, the medical director of psychiatric and addiction medicine at two Tennessee hospitals, pursues some eclectic passions. He’s bred sleek Basenji hunting dogs for show. And last summer, the Tennessee State Museum featured “African Art: The Collection of Jon Draud.”

But the Nashville psychiatrist is also notable for a professional pursuit: During the last four years, the 47-year-old Draud has earnedmore than $1 millionfor delivering promotional talks and consulting for seven drug companies.

Mar 042013
 
ACT UP-Paris: Victoire pour les médicaments génériques en Inde

L’organe d’appel de la propriété intellectuelle a rejeté aujourd’hui la demande du laboratoire Bayer qui souhaitait faire arrêter la production et la vente de versions génériques de la molécule anticancéreuse sorafenib tosylate.
La firme pharmaceutique allemande avait en effet fait appel de la première licence obligatoire indienne autorisant le génériqueur Natco pharma LtD à produire du sorafenib tosylate 97% moins cher que la version commercialisée par Bayer.

Feb 272013
 
Agreement allows pediatric HIV drug to be sold at low cost to countries in need

An agreement announced this morning between a U.N.-backed health organization and a partnership of three pharmaceutical companies will open the license for a pediatric HIV drug to be manufactured and sold at low cost to countries in need. The joint venture between Medicines Patent Pool and ViiV Healthcare — comprised of AIDS research units from [...]

Feb 202013
 
USA - Oscar-nominated documentary explores early years of AIDS epidemic

It’s Oscar week over at The I Files, a YouTube channel curated by our parent organization, the Center for Investigative Reporting, and we’re taking a look at some of this year’s documentary nominees. One in particular, “How to Survive a Plague,” explores a topic of interest for many Bay Area residents: the early days of the AIDS epidemic and [...]

Feb 202013
 
USA - Anthem Blue Cross backs off mail order pharmacy mandate for Californians living with HIV

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, which currently provides medical care and/or services to over 200,000 individuals in 28 countries worldwide, today lauded California’s Anthem Blue Cross for its decision to reverse a recent company policy change that would have forced HIV/AIDS patients covered by the plan to utilize one out-of-state mail [...]

Feb 152013
 
USA - FDA gives priority review status to experimental drug, dolutegravir, for HIV/AIDS

U.S. regulators gave priority review status to an experimental GlaxoSmithKline drug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year seller. The U.S. Food and Drug Administration awards certain drugs priority status when they have the potential to offer significant improvement over existing treatments. The agency is due to give its verdict on whether [...]